Richmond Pharmacology Ltd is proud to announce its participation in the �2nd DIA Cardiac Safety Workshop in Japan,� being held September 5-6, 2011 at Tower Hall Funabori in Tokyo, Japan. The meeting will address the key scientific, clinical and regulatory issues of implementation of ICH-E14 in Japan and bring together experts from multiple disciplines; intended to facilitate an open and productive dialogue between regulatory, industry and academic delegates.As a feature, the first ever formal Japanese Caucasian bridging TQT analysis will be presented by Dr Jorg Taubel, CEO and Principal Investigator of Richmond Pharmacology Ltd. The analysis was carried out jointly between the Department of Pharmacology of Toho University, the Cardiovascular Sciences Research Centre at St Georges University of London and Richmond Pharmacology Ltd. This groundbreaking presentation being held on Day 1, Session 3 from 17h00 to 17h30 promises to be an informative and insightful discussion relating to the recent implementation of ICH-E14.Having successfully completed in excess of 50 studies in Japanese subjects since 2002, many of which have already been used in regulatory submissions in Japan, Richmond Pharmacology Ltd is well positioned to conduct TQT Studies in Japanese subjects outside of Japan and for the conduct of TQT Bridging Studies in a mixed Japanese and Caucasian study populations. To learn more about our specialist expertise in Japanese Studies come meet our team at booth numbers 8-9, where Richmond Pharmacology Ltd will be happy to discuss our capabilities in more detail.If you are interested in attending the 2nd DIA Cardiac Safety Workshop in Japan, click here to register or contact a member of our business development team to arrange a meeting in person. We look forward to seeing you in Tokyo!

Latest news

Richmond Pharmacology Announces Promotion of Dr Priscilla Ochuba to Associate Medical Director

August 1, 2025
Richmond Pharmacology is pleased to announce the promotion of Dr Priscilla Ochuba to Associate Medical Director, effective 1st August 2025.
Read more

Red4Research Blog – Alan’s Story

June 24, 2025
#Red4Research is a global initiative that recognises the essential role of clinical research in improving treatment, outcomes, and the future of medicine.
Read more

Events

JSCPT 2025

5th –6th December 2025
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
View event